FDA Extends Review Of Wyeth/Progenics Methylnaltrexone NDA Until April
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA has pushed back the action date on Wyeth and Progenics' NDA for the subcutaneous formulation of methylnaltrexone, a peripherally acting mu-opioid receptor antagonist, until April 30, the companies announced Jan. 10